Prof. Dr. Michael Heneka
|
|
||||
| Postadresse |
Université du Luxembourg 6, avenue du Swing L-4367 Belvaux |
||||
| Büroadresse | BioTech II, 2.02 | ||||
|
|||||
| Telefon | (+352) 46 66 44 6922 | ||||
Michael Heneka is a board-certified neurologist and clinician-scientist with over 25 years of experience in studying neurodegenerative diseases at experimental, preclinical and clinical levels. He has a long-standing interest in immunology and neuroscience. While the main focus of his work is related to dementia and Alzheimer’s disease, he has also been working on Amyotrophic Lateral Sclerosis and Parkinson’s disease.
At the clinical level, he had established a neurodegenerative outpatient unit at both the University of Münster and the University of Bonn in Germany. From 2016 to 2021, he led the department of Neurodegenerative Disease and Geriatric Psychiatry in Bonn. From January 2022 onwards, he is the Director of the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg and Principal Investigator in the Neuroinflammation group (Heneka Lab)
Last updated on: Mittwoch, den 23. Februar 2022
Education
- Doctoral thesis, Department of Pharmacology and Toxicology, University of Tübingen (1998)
- Medical Degree, University of Tübingen, University of London, University of Lausanne (1996)
- Philosophy Studies, University of Tübingen (1995)
Professional/academic career
University of Bonn, DE
- Professor for Clinical Neurosciences, Head of the Clinical Neuroscience Unit, Director of the Clinical Treatment and Research Center (KBFZ), Department of Neurology (2008-2021)
- Director, Department of Neurodegenerative Disease and Geriatric Psychiatry (2016-2021)
University of Massachusetts Medical School, USA (2012-present)
- Adjunct Prof. of Medicine. Department of Internal Medicine, Division Infectious Diseases and Immunology
University of Münster, DE (2004-2008)
- Professor for Molecular Neurology, Senior Consultant Neurologist, Department of Neurology
University of Bonn, DE (2004)
- Senior Consultant Neurologist
Case Western Reserve University, USA (2003)
- Research Associate Professor at the „Alzheimer Research“, Department of Neurosciences
University of Bonn, DE
- Consultant/senior clinical fellow, Neurophysiology Unit, Department of Neurology (2003)
- Venia legendi/Habilitation for Neurology: Inflammatory mechanism in Alzheimer’s disease: characterization and development of therapeutic strategies (2003)
- Board examination in Neurology (2002)
- Clinical Fellow, Department of Neurology (1999-2001), Department of Psychiatry (2001-2002)
University of Illinois, USA (1998)
- Visiting Scholar at the laboratory for „NeuroAnesthesia Research“
University of Tubingen, DE
- Clinical Fellow, Department of Neurology, 1998
- Residency, Department of Neurology, 1996-1997
Clinical Expertise
University Hospital Bonn, DE (2016-2021)
- Director and medical head of the Department of Neurodegenerative Disease and Geriatric Psychiatry
University Hospital Bonn, DE (2008-2016)
- Head of the section „motoneuron disorders“
- Chief medical supervision of patients with neurodegenerative disease.
- Head of the Clinical Center for Treatment and Reseach (KBFZ).
- Head of the Clinical Neuroscience Unit (CNU)
University of Münster, DE (2004-2008)
- Prof. of Molecular Neurology, Senior Consultant Neurologist
- Head of the Memory Clinic of the Dept. of Neurology.
- Head of the Department of Molecular Neurology.
University of Bonn, DE (2002-2003)
- Senior Consultant Neurologist for Neurophysiology (Funktionsoberarzt)
- Senior Consultant Neurologist
University of Tübingen and University of Bonn, DE (1997-2002)
- Resident, Departments of Neurology
Last updated on: 23 Feb 2022
Scientific participation
- Board Member Kompetenznetz Neurodegenenerative Demenzen, since 2007
- Head of the Clinical Research Group 177 (German Research Council), since 2008
- Editorial Board, Journal of Neurochemistry, 2008-2020
- Editorial Board, Molecular Neurobiology, since 2012
- Associate Editor, Neurology, Neuroimmunology and Neuroinflammation, 2015-2020
- Editorial Board, Alzheimer Research & Therapy, since 2016
- Editorial Board, ASN Neuro, since 2018
- Board Member DFG Exzellenzcluster Immunosensation, since 2018
- Associate Editor, Alzheimer Research & Therapy, since 2019
- Science Advisory Board, Paris Brain Institute, France, since 2017
- Science Advisory Board, Dementia Research Institute, UK, since 2018
Last updated on: 23 Feb 2022
- WO 2005/016339 A1, “Antiinflammatory methods for treatment of Parkinson`s disease”, together with Prof. G.E. Landreth.
- EP09009085.3a: Inhibitors of the nitration of amyloid beta peptides and their uses in the diagnosis and treatment of Alzheimer's disease, 2009
Last updated on: 23 Feb 2022
2023
Reactive microglia are the major source of tumor necrosis factor alpha and contribute to astrocyte dysfunction and acute seizures in experimental temporal lobe epilepsy.; ; ; ; ; ; ; ; ; ;
in Glia (2023), 71(2), 168-186
2022
Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease.; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
in Neuron (2022), 110(6), 1009-10224
Microglia states and nomenclature: A field at its crossroads.; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
in Neuron (2022), 110(21), 3458-3483
